
Opinion|Videos|March 27, 2025
First-Line Therapy for Advanced HCC: The Role of TKIs and ICIs
Author(s)Richard S. Finn, MD, Amit Singal, MD
Panelists discuss how current first-line systemic therapies for advanced hepatocellular carcinoma (HCC) include atezolizumab + bevacizumab and durvalumab + tremelimumab, replacing tyrosine kinase inhibitors (TKIs) like sorafenib and lenvatinib. Emerging combinations with anti–PD-L1 agents enhance efficacy. TKI + immune checkpoint inhibitor (ICI) combinations offer synergistic benefits but pose toxicity, cost, and biomarker challenges.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- Briefly discuss current approved first-line systemic therapies for advanced HCC.
- How are emerging combination strategies, particularly with anti–PD-L1 agents, reshaping the first-line treatment landscape?
- What are the potential advantages of TKI + ICI combinations compared with TKI monotherapy?
- Please also discuss potential challenges.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
The Targeted Pulse: New Standards in Myeloma, Melanoma, and More
2
FDA Accepts BLA for Ivonescimab in Pretreated EGFR-Mutated NSCLC
3
Onvansertib Triplet Shows Dose-Dependent Frontline Benefit in RAS-Mutant Metastatic CRC
4
Pembrolizumab/Lenvatinib Show Efficacy, Safety in Clear Cell Gyn Cancers
5



















